Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Phost’in Therapeutics SAS (Phost’in) today announced that the two companies have entered into an option and license agreement through which Taiho Pharmaceutical will obtain option rights to inlicense PhOx430, a First-in-Class small molecule targeting GnT-V (Nacetylglucosaminyltransferase-V).